Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-21 | Amended | $6,200,000 | $2,700,000 | Debt Only | 06b | SEC link |
| 2025-03-18 | Amended | $5,499,900 | $945,900 | Equity Only | 06b | SEC link |
| 2023-10-27 | New | $3,500,000 | $3,500,000 | Debt Only | 06b | SEC link |
| 2023-01-09 | Amended | $4,554,000 | $1,053,900 | Equity Only | 06b | SEC link |
| 2021-03-23 | New | $3,500,100 | $3,500,100 | Equity Only | 06b | SEC link |
| 2019-12-19 | New | $3,500,100 | $3,500,100 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Benjamin A. Belinka, Jr. | Executive |
| Maribeth Bluyus | Executive |
| Rene Chaze | Director |
| Robert Nagele | Director |
| Mert Sahin | Executive |